Sorrento Therapeutics Passes on $1.17B Offer: PHARMA: Three Bids Made for Co. Working On Opioid Alternative.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Abstract:
      The article informs that Sorrento Therapeutics has rejected a private equity fund's acquisition bid. It mentions that the offer of shares has undervalued the company and was not in the best interest of shareholders. It mentions that Sorrento has planned to ask the U.S. Food and Drug Administration for the OK to begin late-stage clinical trials.